BRIGHTX

Therapeutic Expertise

Twelve therapeutic areas. Real program experience, not a capabilities list.

The Bright Pharmaceutical Services team has been running clinical trials across all major disease areas since 2002. Oncology is our deepest area of expertise — it's the core of CPRIT's mission, and it shows in our team's knowledge of trial design, site qualification, and regulatory nuance. But the operational and therapeutic depth extends across immunology, CNS, cardiovascular, and beyond.

Oncology research

Oncology Core — Solid tumors, liquid tumors, and immuno-oncology.

Featured Specialty

Oncology & Cancer Research

CPRIT-aligned

Solid tumors including breast, lung, colorectal, pancreatic, renal cell, melanoma, and head and neck. Hematologic malignancies including lymphoma, multiple myeloma, AML, and CLL. Modality experience covers checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4), antibody-drug conjugates, CAR-T cell therapies, bispecific antibodies, and small molecule targeted agents. We've managed basket trials, umbrella trials, adaptive seamless Phase II/III designs, and complex tumor-agnostic programs. Our Texas-based oncology team has direct relationships with major Texas cancer centers .

Solid TumorsHematologic MalignanciesImmuno-OncologyCheckpoint InhibitorsADCsCAR-TBispecificsBasket & Adaptive TrialsPhase I–IVCPRIT-aligned

Additional Therapeutic Areas

Backed by Bright Pharmaceutical Services experience since 2002.

Autoimmune & Inflammatory

Phase II–III experience in rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Complex protocol designs including biomarker-stratified cohorts, patient-reported outcome endpoints, and long-term extension studies.

Cardiovascular

Heart failure, atrial fibrillation, acute coronary syndrome, and lipid-lowering programs. Cardiac endpoint adjudication, Holter monitoring coordination, and device trial experience across implantables and interventional procedures.

Central Nervous System

Alzheimer's disease, Parkinson's disease, epilepsy, major depressive disorder, schizophrenia, and chronic pain. Experienced with complex rating scale training programs, centralized rater models, and early-phase CNS designs that require specialized site qualification.

Dermatology

Atopic dermatitis, psoriasis, alopecia areata, and other inflammatory skin conditions. Both topical and systemic biologics. Photographic endpoint management, EASI/PASI/IGA scoring standardization, and dermatology site network activation.

Endocrinology & Metabolic

Type 1 and Type 2 diabetes, obesity, thyroid disorders, and other metabolic indications. Continuous glucose monitor integration, IVGTT protocols, and lab standardization across international sites.

Infectious Diseases

Antiviral, antibacterial, antifungal, and vaccine trials. Experience with adaptive Phase II/III designs, DSMB interactions for safety-intensive programs, and rapid site activation for outbreak-response studies.

Internal Medicine

Hepatology (NASH/MASH, cirrhosis, HCV/HBV), nephrology (CKD, IgA nephropathy), and pulmonology programs. Liver biopsy coordination, renal endpoint adjudication, and spirometry standardization.

Ophthalmology

Age-related macular degeneration, diabetic macular edema, glaucoma, and dry eye disease. Specialized site qualification for ETDRS charts and OCT imaging, reading center integration, and intravitreal injection protocol management.

Respiratory

Asthma, COPD, idiopathic pulmonary fibrosis, and rare pulmonary diseases. Spirometry standardization (ATS/ERS guidelines), FeNO testing coordination, and exacerbation-based endpoint adjudication.

Women's Health

Obstetrics, gynecology, endometriosis, uterine fibroids, and hormone-related indications. Experience with reproductive endpoint studies, device-based interventions, and programs requiring specialized informed consent processes.

Specialty Populations

Medical devices (PMA and 510(k) pathways), in vitro diagnostics, pediatric studies, geriatric studies, ethnic bridging studies, and surgical interventions. Regulatory strategy and clinical evidence generation across FDA and international submissions.

Texas Investigators

Join our statewide site network.

We're actively recruiting Texas-based investigators across all therapeutic areas — with particular interest in oncology-specialized sites. Network participation means access to industry-sponsored trials, dedicated site management support, and a CRO that knows how to work with academic medical centers and community oncology practices alike.